Engineering antibodies for clinical applications

被引：92

作者：

Jain, Maneesh ^{[1
]}

Kamal, Neel ^{[1
]}

Batra, Surinder K. ^{[1
]}

机构：

[1] Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Dept Pathol & Microbiol,Eppley Inst Res Canc & Al, Omaha, NE 68198 USA

来源：

TRENDS IN BIOTECHNOLOGY | 2007年 / 25卷 / 07期

关键词：

D O I：

10.1016/j.tibtech.2007.05.001

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Molecular engineering has contributed immensely to the clinical success of antibodies in recent years. The modular structure of antibodies has permitted their modification in numerous ways, to meet various clinical requirements. With the help of antibody engineering, it has been possible to modify the molecular size, pharma-cokinetics, immunogenicity, binding affinity, specificity and effector function of antibodies. In addition, fusion proteins of antibodies with various proteins and peptides have yielded targeted biological modifiers, toxins and imaging agents. This review focuses on the recent trends in antibody engineering for improving their clinical utility.

引用

页码：307 / 316

页数：10

共 110 条

[1] Monoclonal antibody therapy of cancer [J].

Adams, GP ;

Weiner, LM .

NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157

[2] Characterization of a CC49-based single-chain fragment-β-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT) [J].

Alderson, RF ;

Toki, BE ;

Roberge, M ;

Geng, W ;

Basler, J ;

Chin, R ;

Liu, A ;

Ueda, R ;

Hodges, D ;

Escandon, E ;

Chen, T ;

Kanavarioti, T ;

Babé, L ;

Senter, PD ;

Fox, JA ;

Schellenberger, V .

BIOCONJUGATE CHEMISTRY, 2006, 17 (02) :410-418

[3] Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor [J].

Baral, Toya Nath ;

Magez, Stefan ;

Stijlemans, Benoit ;

Conrath, Katja ;

Vanhollebeke, Benoit ;

Pays, Etienne ;

Muyldermans, Serge ;

De Baetselier, Patrick .

NATURE MEDICINE, 2006, 12 (05) :580-584

[4] Pharmacokinetics and biodistribution of genetically engineered antibodies [J].

Batra, SK ;

Jain, M ;

Wittel, UA ;

Chauhan, SC ;

Colcher, D .

CURRENT OPINION IN BIOTECHNOLOGY, 2002, 13 (06) :603-608

[5] Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein [J].

Bauer, S ;

Adrian, N ;

Williamson, B ;

Panousis, C ;

Fadle, N ;

Smerd, J ;

Fettah, I ;

Scott, AM ;

Pfreundschuh, M ;

Renner, C .

JOURNAL OF IMMUNOLOGY, 2004, 172 (06) :3930-3939

[6] Structure-activity profiles of ab-derived TNF fusion proteins [J].

Bauer, Stefan ;

Adrian, Nicole ;

Fischer, Eliane ;

Kleber, Sascha ;

Stenner, Frank ;

Wadle, Andreas ;

Fadle, Natalie ;

Zoellner, Andy ;

Bernhardt, Rita ;

Knuth, Alexander ;

Old, Lloyd J. ;

Renner, Christoph .

JOURNAL OF IMMUNOLOGY, 2006, 177 (04) :2423-2430

[7] HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].

CARTER, P ;

PRESTA, L ;

GORMAN, CM ;

RIDGWAY, JBB ;

HENNER, D ;

WONG, WLT ;

ROWLAND, AM ;

KOTTS, C ;

CARVER, ME ;

SHEPARD, HM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289

[8] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

[9] A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival [J].

Cohen-Saidon, C ;

Nechushtan, H ;

Kahlon, S ;

Livni, N ;

Nissim, A ;

Razin, E .

BLOOD, 2003, 102 (07) :2506-2512

[10] Efficient cancer therapy with a nanobody-based conjugate [J].

Cortez-Retamozo, V ;

Backmann, N ;

Senter, PD ;

Wernery, U ;

De Baetselier, P ;

Muyldermans, S ;

Revets, H .

CANCER RESEARCH, 2004, 64 (08) :2853-2857

← 1 2 3 4 5 6 7 8 9 10 →